CY1116135T1 - Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια - Google Patents

Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια

Info

Publication number
CY1116135T1
CY1116135T1 CY20151100289T CY151100289T CY1116135T1 CY 1116135 T1 CY1116135 T1 CY 1116135T1 CY 20151100289 T CY20151100289 T CY 20151100289T CY 151100289 T CY151100289 T CY 151100289T CY 1116135 T1 CY1116135 T1 CY 1116135T1
Authority
CY
Cyprus
Prior art keywords
protection
rotaius
vaccine
provides cotton
provides
Prior art date
Application number
CY20151100289T
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Vos Beatrice Arsene Virginie De
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1116135T1 publication Critical patent/CY1116135T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η εφεύρεση παρέχει μέθοδο διέγερσης ανοσοαπόκρισης έναντι στελέχους ροταϊού, η δε μέθοδος περιλαμβάνει χορήγηση σε ένα υποκείμενο μιας σύνθεσης που περιλαμβάνει εξασθενημένο στέλεχος ροταϊού ενός G1P[8] τύπου, η εν λόγω δε σύνθεση δημιουργεί ανοσοαπόκριση έναντι στελέχους ροταϊού ενός G2P[4] τύπου.
CY20151100289T 2005-08-17 2015-03-23 Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια CY1116135T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine
EP10159949.6A EP2233153B1 (en) 2005-08-17 2006-08-15 Rotavirus vaccine inducing heterotypic cross protection

Publications (1)

Publication Number Publication Date
CY1116135T1 true CY1116135T1 (el) 2017-02-08

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100289T CY1116135T1 (el) 2005-08-17 2015-03-23 Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια

Country Status (25)

Country Link
US (1) US20090028828A1 (el)
EP (2) EP2233153B1 (el)
JP (1) JP5519934B2 (el)
KR (1) KR20080036648A (el)
AR (1) AR054916A1 (el)
AU (1) AU2006281566B2 (el)
BR (1) BRPI0615203A2 (el)
CA (1) CA2619751C (el)
CR (1) CR9759A (el)
CY (1) CY1116135T1 (el)
DK (1) DK2233153T3 (el)
EA (1) EA014328B1 (el)
ES (1) ES2534637T3 (el)
HR (1) HRP20150310T1 (el)
IL (1) IL189289A0 (el)
MA (1) MA29700B1 (el)
MX (1) MX2008002270A (el)
NO (1) NO20080754L (el)
PE (1) PE20070235A1 (el)
PL (1) PL2233153T3 (el)
PT (1) PT2233153E (el)
SG (1) SG163571A1 (el)
SI (1) SI2233153T1 (el)
TW (1) TW200740457A (el)
WO (1) WO2007020078A2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
US8241886B2 (en) 2007-09-25 2012-08-14 Aridis Pharmaceuticals Formulations for preservation of rotavirus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
US20140242113A1 (en) * 2011-04-28 2014-08-28 Leonard P. Ruiz, JR. Liquid vaccine preparations
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9060391A (en) * 1990-11-16 1992-06-11 James N. Gamble Institute Of Medical Research Human rotaviruses, vaccines and methods
ES2260046T3 (es) * 1999-08-17 2006-11-01 Glaxosmithkline Biologicals S.A. Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados.
KR20060126917A (ko) * 2003-09-02 2006-12-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신

Also Published As

Publication number Publication date
AU2006281566A1 (en) 2007-02-22
HRP20150310T1 (hr) 2015-06-19
TW200740457A (en) 2007-11-01
EA200800320A1 (ru) 2008-10-30
PL2233153T3 (pl) 2015-06-30
MA29700B1 (fr) 2008-08-01
EA014328B1 (ru) 2010-10-29
PE20070235A1 (es) 2007-04-04
SI2233153T1 (sl) 2015-05-29
CR9759A (es) 2008-05-05
CA2619751A1 (en) 2007-02-22
WO2007020078A2 (en) 2007-02-22
NO20080754L (no) 2008-05-15
MX2008002270A (es) 2008-03-27
PT2233153E (pt) 2015-04-20
JP5519934B2 (ja) 2014-06-11
BRPI0615203A2 (pt) 2011-05-10
US20090028828A1 (en) 2009-01-29
JP2009504701A (ja) 2009-02-05
AR054916A1 (es) 2007-07-25
SG163571A1 (en) 2010-08-30
KR20080036648A (ko) 2008-04-28
ES2534637T3 (es) 2015-04-27
DK2233153T3 (da) 2015-04-27
EP2233153B1 (en) 2015-01-21
EP1915173A2 (en) 2008-04-30
IL189289A0 (en) 2008-06-05
EP2233153A1 (en) 2010-09-29
WO2007020078A3 (en) 2007-05-24
CA2619751C (en) 2016-07-05
AU2006281566B2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
CY1116135T1 (el) Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια
CY1119618T1 (el) Ενωσεις και συνθεσεις ως ρυθμιστικα μορια της tlr δραστηριοτητας
CY1118732T1 (el) Εμβολια κυστιδιων βασει gna1870 για προστασια ευρεως φασματος εναντι νοσων προκαλουμενων απο neisseria meningitidis
MX2019001761A (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis.
ATE426412T1 (de) Adjuvante influenza-vakzine
TW200806316A (en) Yeast-based vaccine for inducing an immune response
BRPI0519000A2 (pt) variantes de il-7 com imunogenicidade reduzida
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
MY149604A (en) C.perfringens alpha toxoid vaccine
MX2010006823A (es) Metodos para el tratamiento de la gota.
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
NO345046B1 (no) Oral doseringsform
DK1830881T3 (da) Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
WO2009044272A3 (en) Laser-based vaccine adjuvants
SG147465A1 (en) Vaccine
EA202191610A1 (ru) Композиции, полученные из сконструированного флагеллина, и их применение
ATE424844T1 (de) Kombinationsvakzine für geflügel
CY1114309T1 (el) Εμβολιο ροταϊου
EA202090781A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ПРОГНОЗИРОВАНИЯ ОТВЕТА НА NaPi2b-ТАРГЕТИРОВАННУЮ ТЕРАПИЮ
MA50737B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
TR201208503U (tr) %100 doğal karasinek tuzağı.